ElexoPharm Receives € 2.1 Million EUROSTARS Grant for Program Targeting Mitochondrial Diseases ("MITOTREAT - E!6654")

FMER_Logo ElexoPharm_Logo

Saarbruecken, Germany, May 21, 2012 / B3C newswire / - A EUROSTARS grant of €2.1 million has been awarded to a transnational consortium consisting of Khondrion BV (Nijmegen), Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen), Pharmacelsus GmbH (Saarbruecken) and ElexoPharm GmbH (Saarbruecken). This grant, which for the German partners comes from the German Federal Ministry of Education and Research (BMBF), will support an ambitious scientific collaboration to discover treatments for mitochondrial diseases with high unmet medical need (approximately 300,000 patients in industrialized countries). 

During the three years’ grant period, each partner of this multidisciplinary European consortium will contribute its expertise to reach their shared goal. ElexoPharm is responsible for the design and synthesis of small pharmaceutical molecules with state of the art in silico modelling and medicinal chemistry technologies. Khondrion acts as the consortium leader and will carry out the in vitro evaluation of the new chemical entities, including screening in their cell-based mitochondrial disease models. Pharmacelsus is going to perform ADME, toxicity and PK studies in their GLP-certified facilities, and the RUNMC will evaluate the best compounds regarding in vivo efficacy in preclinical studies to achieve Proof of Principle. 

"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat these diseases of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, managing director of ElexoPharm.

About ElexoPharm
ElexoPharm GmbH is a German biotech company located in Saarbrücken, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University headed by Professor Rolf Hartmann. ElexoPharm is focused on the preclinical discovery and optimization of novel innovative drugs for human diseases, which are currently not or insufficiently treatable with existing drugs. The largest success of ElexoPharm was the execution of an exclusive license and collaboration agreement with Merck & Co. Inc. for one of its own research projects (development of aldosterone synthase inhibitors for the treatment of cardiovascular diseases) in 2010.

Axel Koch, MBA                               
Managing Director
ElexoPharm GmbH
Im Stadtwald
66123 Saarbruecken
Phone: +49 (0) 681 - 302 68320
Fax: +49 (0) 681 - 910 2894
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
URL: www.elexopharm.de

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.